AI Drug Discovery for Pharma and Biotech

Drug discovery

52

papers

On emerging therapies

Overview

46,XY difference of sex development (DSD) due to 5-alpha-reductase 2 deficiency is a rare autosomal recessive disorder caused by SRD5A2 mutations, impairing testosterone-to-dihydrotestosterone (DHT) conversion. This results in undervirilized external genitalia (e.g., micropenis, hypospadias, or female-appearing genitalia) at birth, with normal Wolffian duct development. Virilization (voice deepening, muscle growth) often occurs at puberty. Diagnosis relies on elevated testosterone/DHT ratios, urinary steroid profiling, and genetic testing [1][3][6].

Population

  • Primarily affects 46,XY individuals; incidence is higher in regions with consanguinity (e.g., Dominican Republic, Papua New Guinea) [6][9].

  • Carrier 46,XX females are asymptomatic but transmit mutations [1][13].

Burden

  • Infertility: Common due to prostate hypoplasia and impaired semen quality; assisted reproduction may be needed [5][6].

  • Mental health: Elevated anxiety/depression risks due to gender dysphoria and social stigma [2][4].

  • Lifelong care: Requires multidisciplinary management (endocrinology, urology, psychology) [9][10].

Therapies

  • Gender assignment: Deferred until puberty when possible, as 60–70% adopt male gender identity post-virilization [4][9].

  • Hormonal therapy: DHT gel or testosterone for penile growth pre-surgery; estrogen for female-affirming care [7][11].

  • Surgical interventions: Hypospadias repair, gonadectomy (if female assignment), or vaginoplasty [4][7].

Categories: rare developmental anomalies during embryogenesis, rare endocrine diseases, rare genetic diseases, rare gynecological and obstetric diseases, rare infertility disorders, rare transplant-related disorders, rare urogenital diseases

Research Papers

52 drug discovery papers about 46,XY difference of sex development due to 5-alpha-reductase 2 deficiency. Recent publications:

52 drug discovery papers about 46,XY difference of sex development due to 5-alpha-reductase 2 deficiency. Recent publications:

categories:

Small molecules

small molecules
2026-05-19 | Clinical characterization and analysis of the SRD5A2 gene in 16 Chinese patients with 5α-reductase type 2 deficiency: a single-center retrospective study.

5α-reductase type 2 deficiency(5α-RD2) is a rare autosomal recessive disorder primarily caused by variants in the SRD5A2 gene. This condition is characterized by a spectrum of undervirilization in 46, XY individuals, ranging from ambiguous genitalia to predominantly male external genitalia with minimal undervirilization. Early diagnosis and effective management of 5α-reductase type 2 deficiency patients are major challenges for healthcare providers. The mutational analysis of SRD5A2 gene is regarded as the gold standard for the diagnosis of the disease. This study aimed to summarize our center's experience with patients diagnosed with 5α-reductase type 2 deficiency due to variations in the SRD5A2 gene and the associated clinical manifestations to enhance clinicians' awareness of this condition. We conducted a retrospective single-center study by reviewing the medical records of patients diagnosed with 5α-reductase type 2 deficiency after genetic testing between April 2018 and July 2025. All 16 patients presented with ambiguous genitalia at birth and received diagnoses between the ages of 3 months and 11 years and 3 months. Of these patients, ten exhibited micropenis accompanied by hypospadias, six displayed an isolated micropenis, and six had either bilateral or unilateral cryptorchidism. Additionally, six patients had an underdeveloped scrotum. All affected individuals had a 46, XY karyotype and tested positive for the SRY gene, with two patients initially raised as female. The testosterone/dihydrotestosterone (T/DHT) ratios after human chorionic gonadotropin (hCG) stimulation ranged from 1.5- to 38.6-fold above the baseline values. This study identified ten distinct pathogenic variants of the SRD5A2 gene, including nine previously reported variants p.Gln6Ter, p.Gly66Arg, p.(Tyr128Cys), p.Asn193Ser, p.Gly196Ser, p.Gly203Ser, p.Phe219Serfs*60, p.Arg227Gln, and p.Arg246Gln and one novel variant p.(Cys119Arg), which expands the spectrum of known SRD5A2 variants. This study provides insights into genotype-phenotype correlations in a cohort of 16 Chinese patients diagnosed with 5α-reductase type 2 deficiency and summarized the enzymatic activity of the identified genetic variants. Identifying variants associated with 5α-reductase type 2 deficiency will facilitate genetic counseling for at-risk families and enable prenatal diagnosis, thus empowering parents to make informed decisions and allowing healthcare providers to tailor treatment strategies effectively.

Open article ↗



2026-02-05 | [Clinical, hormonal and molecular genetic characteristics of 18 cases of disorders of sex development (DSD) 46,XY associated with variants in the SRD5A2 gene].

Among the disorders of sex development (DSD) with karyotype 46,XY, there is a group of diseases caused by defects of androgen synthesis. The last stage of in the synthesis of androgens is the conversion of testosterone into a more active androgen dihydrotestosterone, which occurs under the influence of the enzyme 5α-reductase type II (SRD5A2). SRD5A2 deficiency is a rare disease with autosomal recessive inheritance. To give a clinical and molecular genetic characterization of 14 new cases with confirmed molecular diagnosis of SRD5A2 deficiency, as well as 4 cases of DSD 46,XY, where monoallelic changes in the SRD5A2 gene were detected. The study included 310 patients with DSD 46,XY. Molecular genetic analysis was performed using the NGS method using a targeted panel for multiplex amplification and subsequent sequencing of the coding regions of the following genes: AKR1C2, AKR1C4, AMH, AMHR2, AR, ARX, ATRX, CBX2, CYB5A, CYP11A1, CYP17A1, DHCR7, DHH, EMX2, ESR2, FGD1, FGF9, FGFR2, FKBP4, FOXF2, FOXL2, HOXA13, HSD17B3, HSD3B2, ICK, LHCGR, LHX1, LHX9, MAMLD1, MAP3K1, MID1, NR0B1, NR5A1, POR, PTGDS, SOX9, SRD5A2, SRY, STAR, SUPT3H, TSPYL1, WNT4, WT1, ZFPM2. By molecular genetic analysis 16 different variants were identified in the SRD5A2 gene (2 in several families), 4 of which had not been previously described. The study highlights the importance of molecular genetic analysis in the differential diagnosis of DSD 46,XY.

Open article ↗



2025-10-17 | 5-Alpha Reductase Deficiency - An Uncommon Disorder of Sexual Development: A Case Study of Four Turkish Patients within a Family.

5-alpha reductase deficiency is an inherited autosomal recessive disorder that can present with severe masculinization defects and ambiguous genitalia. Up to more than 100 mutations have been reported, but phenotype and genotype associations have not been directly evidenced. Testosterone-to-dihydrotestosterone (T/DHT) ratio is a clinically diagnostic test, and the cut-off value is expected to be higher than 10. This brief report of 4 patients with SRD5A2 deficiency in the same family has focused on the clinical and biochemical features of patients with the same mutation. A 14-year-old patient with c193G>C, p. Ala65Pro in SRD5A2 gene had primary amenorrhea and bilateral palpable mass in the inguinal canal. After a detailed physical examination and karyotype analysis, the patient was diagnosed with SRD5A2 deficiency with a 46, XY karyotype. In addition, the other affected siblings had the same clinical phenotype and low masculinization score. T/DHT ratio of all siblings was 14.5, 2.1, 3.7, and 19.2, respectively. Although all of them had the same genetic mutations with a homozygous pattern (c193G>C, p. Ala65Pro), a different T/DHT ratio was observed in our study. The definitive diagnosis of SRD5A2 deficiency requires molecular testing, but it is currently not available in some centers. Therefore, clinical phenotype and biochemical screening, especially the T/DHT ratio, should be used for evaluating this hereditary syndrome. However, we must consider that the diagnostic sensitivity of the stimulated T/DHT ratio can be affected by various factors, such as age, ethnicity, or the presence of residual enzyme activity.

Open article ↗



2025-08-21 | Molecular Characterization of Steroid 5 Alpha-Reductase 2 (SRD5A2) Gene Variant in Indian Patients with Disorder of Sexual Development.

The 5 alpha-reductase deficiency is one of the significant causes of the disorders of sex development (DSD) in individuals bearing 46 XY chromosomes. The conversion of testosterone into dihydrotestosterone is impaired on account of this enzyme deficiency. The mutations in the steroid 5 alpha-reductase type 2 gene (SRD5A2) result in the deficiency of this enzyme. We hereby report three cases of DSD presented in the Pediatric Department of Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab. The current study was carried out to identify the subtype of DSD in children born to non-consanguineous parents of two families recruited from South West Punjab. Proband 1, belonging to Family 1, was 4.5 years old, whereas Probands 2 and 3 from Family 2 were siblings of 4 years and 2 years of age. All the patients presented with clitoral enlargement and other features, including palpable swellings in the labia majora and bilateral labioscrotal folds. The DNA of the affected children was subjected to exome sequencing. All three were found to be homozygous for c.737G > A: p.R246Q alteration. This was confirmed by Sanger Sequencing and, at the same time, parents were found to be heterozygous. The clinical examination, radiological investigation, hormonal profiling, and the mutation confirmed that all the probands were affected with pseudo vaginal perineoscrotal hypospadias, a subtype of DSD.

Open article ↗



2025-02-12 | Molecular genetic diagnosis and surgical management in a cohort of children with 46,XY disorders/differences of sex development.

A firm diagnosis revealing the etiology of disorders/differences of sex development (DSD) is most helpful in guiding clinical management. The aim of this study is to investigate molecular genetic diagnoses and surgical treatment in a cohort of children with 46,XY DSD. A retrospective study was conducted on children with 46,XY DSD. They were referred to a tertiary surgical center during the period between 2011 and 2022 and were found to have genetic alterations, which were considered etiologies for their DSD. Data on clinical presentations, sex of rearing, genetic findings, surgical treatment, and comorbidities were collected and reviewed. A total of 21 patients were included in the study: 11 and 10 were reared as male and female, respectively. Genetic alterations were found as the causes for androgen insensitivity syndrome (n = 4), 5-alpha reductase type II deficiency (n = 5), 17-beta hydroxysteroid dehydrogenase III deficiency (n = 1), 17-alpha hydroxylase deficiency (n = 1), and gonadal dysgenesis (n = 10). Of those with gonadal dysgenesis, the genetic alterations were NR5A1 mutation/deletion (n = 3), DMRT1 deletion (n = 4), WT1 mutation (n = 2), and DAX1 duplication (n = 1). A total of 20/21 patients underwent one or more surgical procedures including hypospadias repair (n = 10), gonadectomy (n = 11), gonadal biopsy (n = 4), hernia repair (n = 4), orchidopexy (n = 1), and feminizing genitoplasty (n = 1). A total of 5/21 had germ cell neoplasms in one or both gonads. A total of 8/10 patients with gonadal dysgenesis had comorbidities involving other systems. Of the whole group, seven patients were found to inherit genetic alterations from their parents. Molecular genetic diagnosis enhances the understanding of etiology, improves diagnostic accuracy, and provides precise guidance in the counseling and surgical management of children with 46,XY DSD.

Open article ↗



small molecules
2026-05-19 | Clinical characterization and analysis of the SRD5A2 gene in 16 Chinese patients with 5α-reductase type 2 deficiency: a single-center retrospective study.

5α-reductase type 2 deficiency(5α-RD2) is a rare autosomal recessive disorder primarily caused by variants in the SRD5A2 gene. This condition is characterized by a spectrum of undervirilization in 46, XY individuals, ranging from ambiguous genitalia to predominantly male external genitalia with minimal undervirilization. Early diagnosis and effective management of 5α-reductase type 2 deficiency patients are major challenges for healthcare providers. The mutational analysis of SRD5A2 gene is regarded as the gold standard for the diagnosis of the disease. This study aimed to summarize our center's experience with patients diagnosed with 5α-reductase type 2 deficiency due to variations in the SRD5A2 gene and the associated clinical manifestations to enhance clinicians' awareness of this condition. We conducted a retrospective single-center study by reviewing the medical records of patients diagnosed with 5α-reductase type 2 deficiency after genetic testing between April 2018 and July 2025. All 16 patients presented with ambiguous genitalia at birth and received diagnoses between the ages of 3 months and 11 years and 3 months. Of these patients, ten exhibited micropenis accompanied by hypospadias, six displayed an isolated micropenis, and six had either bilateral or unilateral cryptorchidism. Additionally, six patients had an underdeveloped scrotum. All affected individuals had a 46, XY karyotype and tested positive for the SRY gene, with two patients initially raised as female. The testosterone/dihydrotestosterone (T/DHT) ratios after human chorionic gonadotropin (hCG) stimulation ranged from 1.5- to 38.6-fold above the baseline values. This study identified ten distinct pathogenic variants of the SRD5A2 gene, including nine previously reported variants p.Gln6Ter, p.Gly66Arg, p.(Tyr128Cys), p.Asn193Ser, p.Gly196Ser, p.Gly203Ser, p.Phe219Serfs*60, p.Arg227Gln, and p.Arg246Gln and one novel variant p.(Cys119Arg), which expands the spectrum of known SRD5A2 variants. This study provides insights into genotype-phenotype correlations in a cohort of 16 Chinese patients diagnosed with 5α-reductase type 2 deficiency and summarized the enzymatic activity of the identified genetic variants. Identifying variants associated with 5α-reductase type 2 deficiency will facilitate genetic counseling for at-risk families and enable prenatal diagnosis, thus empowering parents to make informed decisions and allowing healthcare providers to tailor treatment strategies effectively.

Open article ↗



2026-02-05 | [Clinical, hormonal and molecular genetic characteristics of 18 cases of disorders of sex development (DSD) 46,XY associated with variants in the SRD5A2 gene].

Among the disorders of sex development (DSD) with karyotype 46,XY, there is a group of diseases caused by defects of androgen synthesis. The last stage of in the synthesis of androgens is the conversion of testosterone into a more active androgen dihydrotestosterone, which occurs under the influence of the enzyme 5α-reductase type II (SRD5A2). SRD5A2 deficiency is a rare disease with autosomal recessive inheritance. To give a clinical and molecular genetic characterization of 14 new cases with confirmed molecular diagnosis of SRD5A2 deficiency, as well as 4 cases of DSD 46,XY, where monoallelic changes in the SRD5A2 gene were detected. The study included 310 patients with DSD 46,XY. Molecular genetic analysis was performed using the NGS method using a targeted panel for multiplex amplification and subsequent sequencing of the coding regions of the following genes: AKR1C2, AKR1C4, AMH, AMHR2, AR, ARX, ATRX, CBX2, CYB5A, CYP11A1, CYP17A1, DHCR7, DHH, EMX2, ESR2, FGD1, FGF9, FGFR2, FKBP4, FOXF2, FOXL2, HOXA13, HSD17B3, HSD3B2, ICK, LHCGR, LHX1, LHX9, MAMLD1, MAP3K1, MID1, NR0B1, NR5A1, POR, PTGDS, SOX9, SRD5A2, SRY, STAR, SUPT3H, TSPYL1, WNT4, WT1, ZFPM2. By molecular genetic analysis 16 different variants were identified in the SRD5A2 gene (2 in several families), 4 of which had not been previously described. The study highlights the importance of molecular genetic analysis in the differential diagnosis of DSD 46,XY.

Open article ↗



2025-10-17 | 5-Alpha Reductase Deficiency - An Uncommon Disorder of Sexual Development: A Case Study of Four Turkish Patients within a Family.

5-alpha reductase deficiency is an inherited autosomal recessive disorder that can present with severe masculinization defects and ambiguous genitalia. Up to more than 100 mutations have been reported, but phenotype and genotype associations have not been directly evidenced. Testosterone-to-dihydrotestosterone (T/DHT) ratio is a clinically diagnostic test, and the cut-off value is expected to be higher than 10. This brief report of 4 patients with SRD5A2 deficiency in the same family has focused on the clinical and biochemical features of patients with the same mutation. A 14-year-old patient with c193G>C, p. Ala65Pro in SRD5A2 gene had primary amenorrhea and bilateral palpable mass in the inguinal canal. After a detailed physical examination and karyotype analysis, the patient was diagnosed with SRD5A2 deficiency with a 46, XY karyotype. In addition, the other affected siblings had the same clinical phenotype and low masculinization score. T/DHT ratio of all siblings was 14.5, 2.1, 3.7, and 19.2, respectively. Although all of them had the same genetic mutations with a homozygous pattern (c193G>C, p. Ala65Pro), a different T/DHT ratio was observed in our study. The definitive diagnosis of SRD5A2 deficiency requires molecular testing, but it is currently not available in some centers. Therefore, clinical phenotype and biochemical screening, especially the T/DHT ratio, should be used for evaluating this hereditary syndrome. However, we must consider that the diagnostic sensitivity of the stimulated T/DHT ratio can be affected by various factors, such as age, ethnicity, or the presence of residual enzyme activity.

Open article ↗



2025-08-21 | Molecular Characterization of Steroid 5 Alpha-Reductase 2 (SRD5A2) Gene Variant in Indian Patients with Disorder of Sexual Development.

The 5 alpha-reductase deficiency is one of the significant causes of the disorders of sex development (DSD) in individuals bearing 46 XY chromosomes. The conversion of testosterone into dihydrotestosterone is impaired on account of this enzyme deficiency. The mutations in the steroid 5 alpha-reductase type 2 gene (SRD5A2) result in the deficiency of this enzyme. We hereby report three cases of DSD presented in the Pediatric Department of Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab. The current study was carried out to identify the subtype of DSD in children born to non-consanguineous parents of two families recruited from South West Punjab. Proband 1, belonging to Family 1, was 4.5 years old, whereas Probands 2 and 3 from Family 2 were siblings of 4 years and 2 years of age. All the patients presented with clitoral enlargement and other features, including palpable swellings in the labia majora and bilateral labioscrotal folds. The DNA of the affected children was subjected to exome sequencing. All three were found to be homozygous for c.737G > A: p.R246Q alteration. This was confirmed by Sanger Sequencing and, at the same time, parents were found to be heterozygous. The clinical examination, radiological investigation, hormonal profiling, and the mutation confirmed that all the probands were affected with pseudo vaginal perineoscrotal hypospadias, a subtype of DSD.

Open article ↗



2025-02-12 | Molecular genetic diagnosis and surgical management in a cohort of children with 46,XY disorders/differences of sex development.

A firm diagnosis revealing the etiology of disorders/differences of sex development (DSD) is most helpful in guiding clinical management. The aim of this study is to investigate molecular genetic diagnoses and surgical treatment in a cohort of children with 46,XY DSD. A retrospective study was conducted on children with 46,XY DSD. They were referred to a tertiary surgical center during the period between 2011 and 2022 and were found to have genetic alterations, which were considered etiologies for their DSD. Data on clinical presentations, sex of rearing, genetic findings, surgical treatment, and comorbidities were collected and reviewed. A total of 21 patients were included in the study: 11 and 10 were reared as male and female, respectively. Genetic alterations were found as the causes for androgen insensitivity syndrome (n = 4), 5-alpha reductase type II deficiency (n = 5), 17-beta hydroxysteroid dehydrogenase III deficiency (n = 1), 17-alpha hydroxylase deficiency (n = 1), and gonadal dysgenesis (n = 10). Of those with gonadal dysgenesis, the genetic alterations were NR5A1 mutation/deletion (n = 3), DMRT1 deletion (n = 4), WT1 mutation (n = 2), and DAX1 duplication (n = 1). A total of 20/21 patients underwent one or more surgical procedures including hypospadias repair (n = 10), gonadectomy (n = 11), gonadal biopsy (n = 4), hernia repair (n = 4), orchidopexy (n = 1), and feminizing genitoplasty (n = 1). A total of 5/21 had germ cell neoplasms in one or both gonads. A total of 8/10 patients with gonadal dysgenesis had comorbidities involving other systems. Of the whole group, seven patients were found to inherit genetic alterations from their parents. Molecular genetic diagnosis enhances the understanding of etiology, improves diagnostic accuracy, and provides precise guidance in the counseling and surgical management of children with 46,XY DSD.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.